Innovative Cardiac Solutions Anteris Technologies is at the forefront of revolutionizing cardiac care with its biomimetic DurAVR THV and advanced anti-calcification technology, creating opportunities to target clinics and hospitals seeking next-generation minimally invasive valve solutions.

Recent Clinical Achievements The launch of one-year clinical outcomes for DurAVR at TCT 2025 highlights strong validation and market interest, making it an opportune moment to engage with early adopters and clinical trial centers involved in innovative heart valve therapies.

Expansion and Market Growth Recent office expansions across the US and Europe, along with plans to scale trials, indicate an increasing footprint and readiness to partner with healthcare providers and distribution channels across North America and Europe.

Strong Financial Position With revenue estimates between 10 and 25 million dollars and recent funding of 24 million dollars, Anteris is well-capitalized to support the adoption and integration of its novel valve technologies in new healthcare facilities and regions.

Leadership and Strategic Direction The addition of experienced directors like David Roberts and Gregory Moss emphasizes strategic growth and innovation, offering opportunities to align with decision-makers driving the adoption of advanced structural heart devices.